Abstract
Background
Ovarian cancer is the 5(th) most common cause of deaths in the women among gynecological tumors. There are many growing evidences that stress and other behavioral factors may affect cancer progression and patient survival. The purpose of this study is to determine the key role of matrix metalloproteinases (MMPs), and cytokines in the aggregation and progression of ovarian cancer.
Methodology
Stress variables (MDA, AGEs, AOPPs, NO), profile of antioxidants (SOD, Catalase, Vitamin E & A, GSH, GRx, GPx) and inflammatory biomarkers (MMP-9, MMP-2, MMP-11, IL-1 alpha and TNF-alpha) were biochemically assessed from venous blood of fifty ovarian cancer patients and twenty healthy control subjects. The results of all parameters were analyzed statistically by independent sample t-test.
Results
The results of the study demonstrated that the levels of stress variables like MDA (3.38 +/- 1.12nmol/ml), AGEs (2.72 +/- 0.22 ng/ml), AOPPs (128.48 +/- 27.23 ng/ml) and NO (58.71 +/- 8.67 ng/ml) were increased in the patients of ovarian cancer as compared to control individuals whereas the profile of antioxidants like SOD, Catalase, Vitamin E, Vitamin A, GSH andGRx were decreased in ovarian cancer patients (0.11 +/- 0.08 mu mol/mol, 2.41 +/- 1.01 mu mol/mol of protein, 0.22 +/- 0.04 mu g/ml, 45.84 +/- 9.07 mu g/ml, 4.88 +/- 1.18 mu g/ml, 5.33 +/- 1.26 mu mol/ml respectively). But the level of GPx antioxidant was increased in ovarian cancer patients (6.58 +/- 0.21 mu mol/ml). Moreover the levels of MMP-9 (64.87 +/- 5.35 ng/ml), MMP-2 (75.87 +/- 18.82 ng/ml) and MMP-11 (63.58 +/- 8.48 ng/ml) were elevated in the patients. Similarly, the levels of various cytokines TNF-alpha and IL-1 alpha were also increased in the patients of ovarian cancer (32.17 +/- 3.52 pg/mI and 7.04 +/- 0.85 pg/mI respectively).
Conclusion
MMPs are commonly expressed in ovarian cancer which are potential extrapolative biomarkers and have a major role in metastasis. Due to oxidative stress, different cytokines are released by tumor associated macrophages (TAMS) that result in the cancer progression. Consequently, tissue inhibitors of matrix metalloproteinases (TIMPs) are the valuable therapeutic approaches to complement conservative anticancer strategies.